There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biora Therapeutics (BIOR – Research Report) and IN8bio (INAB – Research Report) with bullish sentiments.
Biora Therapeutics (BIOR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Biora Therapeutics, with a price target of $65.00. The company’s shares closed last Thursday at $2.80, close to its 52-week low of $1.95.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Biora Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $65.00.
See the top stocks recommended by analysts >>
IN8bio (INAB)
Mizuho Securities analyst Mara Goldstein assigned a Buy rating to IN8bio today and set a price target of $12.00. The company’s shares closed last Thursday at $1.58, close to its 52-week low of $1.38.
According to TipRanks.com, Goldstein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IN8bio with a $13.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BIOR:
- Biora Therapeutics announces preliminary results from PGN-OB1 program
- Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform
- Largest borrow rate increases among liquid names
- Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress
- Biora Therapeutics presents data from its PM-611 study
